Nebenwirkungen · Vaxneuvance
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 6
HOS-147683 · Präparat HOS-099718
The most frequent adverse reactions are pyrexia ≥38 °C (75%), irritability (75%), somnolence (55%), injection-site pain (44%), injection-site erythema (42%), decreased appetite (38%), injection-site induration (28%) and injection-site swelling (28%). The majority of adverse reactions were mild to moderate (based on intensity or size) and of short duration (≤3 days). Severe reactions (defined as being extremely distressed or unable to do usual activities or size of injection-site reaction >8 cm) occurred in ≤4% of infants and children following any dose, with the exception of irritability which occurred in 11% of participants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T14:19:00Z · SHA-256 8c806efad2c6480965326c02c35aa390b1a5f1070feca6a9495a17a403d294b7 · Passage a043847f4dd162f45c3e03c531e3566fa5647626d63285ba0d4bd044376bd255 · Zeichen 470–1103 im Abschnitt